Bliv presents several different entry points into GLP-1 care: a consultation headline starting as low as $58 a month, semaglutide advertised as low as $116 a month, tirzepatide as low as $199, and financing from $29 a month. These are not interchangeable prices. For an adult comparing cash-pay options, the central question is which amount buys which service, for how long, and with what payment obligation. The supplied documents do not fully reconcile those figures.
This documentary review examines Bliv through that budgeting problem rather than treating its smallest advertised number as the cost of treatment. Sources were consulted October 19, 2026; the supplied terms and policies identify an October 15, 2026 effective date. They describe an online intake, independent medical groups, pharmacy fulfillment, automatic subscription renewals, and separate refund rules for evaluations and medication. Those details help explain the purchase, although a personalized checkout quote remains necessary to establish the actual product and total charge.
At a glance
- Medicine-specific advertised prices
- Semaglutide is advertised as low as $116 per month and tirzepatide as low as $199 per month, each dependent on plan structure and eligibility.Sources: [3]
- Other monthly figures
- A consultation headline starts as low as $58 per month; eligible-plan financing starts as low as $29 per month. Neither establishes the complete treatment cost.Sources: [3]
- Self-pay structure
- Clinical services and prescription products are self-pay. Unless expressly stated, neither the operator nor the medical groups bill insurance, Medicare, or Medicaid.Sources: [5]
- Renewals
- Paid subscriptions renew automatically at the then-current price. Subscription cancellation does not itself cancel pending prescription orders, laboratory orders, or appointments.Sources: [5]
- Medication refund boundary
- Medication is not charged before prescription approval. A full refund is available before the prescription is transmitted to the pharmacy; after transmission, medication is nonrefundable.Sources: [5]
Start with the price attached to the medicine
The clearest product-linked figures are the semaglutide and tirzepatide listings: respectively, “as low as” $116 and $199 per month. Both carry the qualification “based on plan structure and eligibility.” These are conditional minimums, not universal prices or confirmed first charges. The supplied evidence does not identify the route, presentation, concentration, additional ingredients, or supply quantity corresponding to either figure. That prevents a like-for-like comparison with a fully specified prescription elsewhere.
The $58 monthly consultation headline needs separate treatment. Its accompanying text describes completing an intake for review by a U.S.-licensed provider, but does not establish which product, supply, or commitment produces that price. A limited-time “50% OFF” promotion also appears without a clear eligible product, reference price, or duration. There is not enough documentation to label $58 an introductory medication price or calculate how the promotion changes either medicine-specific minimum.
Before paying, obtain the first amount due, the services it purchases, and the later charge in writing. Bliv's terms say prices, billing frequency, renewal conditions, and inclusions appear at purchase, making that screen especially important. Our guide to why the first payment can differ from the advertised monthly price explains the distinction. Here, the evidence supports reporting all the advertised figures—not selecting the lowest one as a complete price.
| Advertised item | Published figure | Condition or unresolved detail |
|---|---|---|
| Semaglutide | As low as $116 per month | Plan structure and eligibility apply; formulation, route, and quantity are unspecified. |
| Tirzepatide | As low as $199 per month | Plan structure and eligibility apply; formulation, route, and quantity are unspecified. |
| Consultation headline | Starting as low as $58 per month | The block does not establish product, supply, or commitment. |
| Pay-later options | As low as $29 per month | Eligible plans and eligibility apply; financed principal and total are unspecified. |
| Limited-time promotion | 50% off | Eligible product, reference price, and promotional duration are unspecified. |
Financing changes the payment schedule, not the missing total
Bliv advertises CareCredit at 0% over 24 months and Klarna split payments within a pay-later offering starting as low as $29 per month. The offer is restricted to eligible plans and depends on plan structure and eligibility. Although the page also advertises “Instant approval,” that is Bliv's commercial claim, not confirmation that every applicant qualifies. The supplied material does not identify the financed principal or the complete financing agreement.
The $29 figure therefore should not be read as an alternative medicine price directly comparable with $116 or $199. Nor does a 24-month financing term establish 24 months of medication, clinical follow-up, or a treatment commitment. A useful financing quote would separately state the purchase being financed, payment schedule, total obligation, and what happens to the financing if a clinical service or medication order is canceled. Those details are not resolved here.
The underlying service is self-pay. Bliv's terms say neither Metabody Services nor the medical groups bill insurance, Medicare, or Medicaid unless expressly stated. They leave open possible reimbursement or HSA/FSA use but make no eligibility representation. Budgeting should therefore begin with the documented cash obligation, not presumed reimbursement. The distinction between accepting insurance and a patient's possible reimbursement claim is covered in our insurance and self-pay questions.
Establish what the payment includes—and who supplies it
Bliv's contracting entity is Metabody Services, LLC, which describes itself as a technology and management company rather than a healthcare provider. Its terms assign evaluations, diagnoses, treatment plans, prescriptions, laboratory orders, refills, and follow-up to Metabody Medical P.A., affiliated professional entities, and their clinicians. That division matters when checking a bill: platform access, professional care, and prescription products are different responsibilities even when arranged through one branded service.
The terms distinguish free features, paid subscriptions, one-time purchases, and payments for clinical services and prescription products. They do not provide a complete GLP-1 package breakdown in the supplied evidence. The evaluation fee, laboratory inclusions, supplies, and any required prepayment remain unresolved. Do not assume everything listed on the website is bundled into a medicine's monthly minimum. A written quote should identify included services and any separately payable components.
Some supporting services are documented, but their frequency or price is not. Bliv advertises ongoing clinical support and a Skool community with dietitian-led nutrition guidance and a user forum. Laboratory tests, when ordered, are performed by independent laboratories described as CLIA-certified, with results delivered through the platform and to the clinician. Our guide to included program costs offers a framework for separating these features from services your specific purchase actually covers.
Follow the evaluation before assuming a prescription
Bliv describes an online medical intake reviewed by a U.S.-licensed provider, with “No Phone Calls. No Video visit.” Its advertised sequence is health questions, clinician review, and a prescription if appropriate, usually within a day. That describes the marketed pathway rather than guaranteed acceptance or prescribing. The terms explicitly allow a clinician to request more information, laboratory testing, or an in-person visit, decline treatment, or discontinue it using professional judgment.
Basic service eligibility requires being at least 18, able to form a binding contract, and both resident in and physically located in the United States when using the service. The supplied documents do not establish Bliv's complete GLP-1 clinical eligibility criteria. Before care, patients must consent to telehealth and acknowledge the medical groups' privacy notice. The linked telehealth consent itself was not supplied, leaving its state-specific conditions outside this review.
The entity table assigns separate medical organizations to California, New Jersey and New York, Kansas, Colorado, and Texas, with Metabody Medical P.A. assigned elsewhere. That table is not proof of current access in every state: services depend on licensed clinician availability, and the terms permit state restrictions. For cost planning, confirm current state availability before interpreting an advertised offer as purchasable, and establish whether any requested testing or outside visit creates additional expense.
Confirm the actual product behind the monthly quote
Bliv's commercial page says medications prescribed through it are compounded and dispensed by licensed U.S. pharmacies under valid prescriptions. Its terms use narrower wording: some medications may be compounded. Neither statement identifies the exact preparation for a particular order. The supplied evidence also does not name the pharmacy that would fulfill that order. Ask for the product's formulation, route, presentation, concentration, ingredients, quantity, and pharmacy before treating two price quotes as equivalent purchases.
The terms say a clinician will prescribe a compounded medication only when considered clinically appropriate and will discuss the reasons. They place the preparing pharmacy's name and contact information on the prescription label and in order details. Pharmacy partners are selected by the medical groups and are independent of the platform operator; the terms allow licensed U.S. pharmacies or outsourcing facilities. Dispensing and compounding are distinct activities, so the role of the particular facility still matters.
FDA says compounded drugs are not FDA approved and do not undergo its premarket review for safety, effectiveness, and quality. It recommends compounded drugs when an individual's medical needs cannot be met by an approved drug, with a prescription and state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence, and it is not an approval or disapproval of Bliv. Similarly, Bliv's promotional appetite-control and results language is not independent evidence of outcomes for its preparations.
Read renewal and refund rules as separate decisions
Bliv advertises no long-term commitments or cancellation fees, but paid subscriptions automatically renew at the then-current price until canceled. Cancellation is available through account settings, applicable app-store subscription settings, or support, and takes effect at the current billing period's end. Access continues until then. The supplied evidence does not establish a universal GLP-1 billing interval or a price lock, so neither should be inferred from the word “monthly” in advertising.
Subscription cancellation does not itself cancel a pending prescription, laboratory order, or clinical appointment. Already charged subscription fees, program fees, and AI credits generally are not refunded or prorated, subject to state-law requirements or purchase-specific exceptions. The terms provide a refund of prepaid unused amounts if Bliv terminates an account without cause or discontinues a paid service in the patient's state. Our cancellation and refund guide explains why stopping future renewals and recovering prior payments are different questions.
Clinical and medication charges follow different boundaries. An evaluation fee is fully refunded if the clinician declines treatment or finds the patient is not a candidate; after evaluation and an offer of treatment, it generally is not refundable. Medication is charged only after prescription approval and remains fully refundable until transmission to the pharmacy—not until shipment. Approved refunds are issued to the original payment method within 10 business days, which does not guarantee when a bank will post them.
Shipping has its own clock and remedy
Bliv advertises free shipping, discreet packaging, and shipment to the patient's door typically within three to five days. That logistics statement is separate from its usual one-day clinical review. The supplied wording does not clearly establish whether the shipping window starts at approval, pharmacy transmission, or dispatch, or precisely when arrival should occur. Free shipping also says nothing about whether an evaluation, medication, supplies, or other services are included in the advertised monthly amount.
The terms limit shipments to the supplied U.S. address and make the patient responsible for accurate address information, receipt, and proper storage. Prescription products cannot be returned. There is nevertheless a specific problem-order remedy: report a damaged, incorrect, or unusable shipment within seven days and Bliv says it will arrange a no-charge replacement. The terms also disclaim responsibility for delays or damage caused by carriers, or by weather or handling after delivery. They do not explain how that disclaimer interacts with the seven-day replacement promise. If the pharmacy cannot fill a prescription, the terms offer a medication-charge refund or, if preferred, a clinician-approved alternative.
The documents do not detail a carrier or cold-chain procedure. For an injectable GLP-1 shipment that arrives warm or with insufficient refrigeration, FDA explicitly advises not using it and contacting the provider or dispensing pharmacy. That safety instruction should not be replaced by the general no-returns language. The practical preparation is to retain the pharmacy contact information, inspect the delivery promptly, and use Bliv's documented reporting window when requesting its replacement remedy.
Budget for access to people, not just platform features
Bliv advertises phone support and board-certified clinicians; these are website claims, not independently verified credentials in this review. The terms list 888-859-2882 and a mailing address at 2943 Parkway Blvd, Unit 374, West Valley City, Utah 84119. Email addresses are masked in the supplied text, so they cannot be reproduced as working contact paths. Support hours, clinical response times, follow-up frequency, and prescription-renewal requirements remain undocumented in this sample.
The platform's AI assistant is explicitly informational: it does not provide medical advice, diagnosis, treatment, prescriptions, or clinical decisions. Its availability therefore does not establish access to a clinician or replace a defined follow-up service. Bliv's privacy policy says identifiable information, including health information and assistant conversations, is not used to train AI models, while allowing de-identified data to improve its own models and features. These are policy statements rather than an independent privacy audit.
Most medical records are described as accessible in the account. Other copies can be requested from the privacy officer, with a response within 30 days, a possible noticed 30-day extension, and a potential reasonable cost-based copying fee. For ongoing care, NIDDK emphasizes that follow-up concerns tolerance and response, not simply renewed payments. A useful Bliv quote should therefore explain how to reach the clinical team, what follow-up is included, and what additional contact might cost.
Questions & answers
Is Bliv's $58 monthly headline the price of semaglutide?
The supplied evidence does not establish that connection. The $58 headline introduces a GLP-1 consultation, while the semaglutide listing separately advertises as low as $116 per month, depending on plan structure and eligibility. The 50%-off promotion does not explain the relationship. Ask for the exact first charge and subsequent charge rather than assuming $58 purchases a particular medication supply.
Can I use insurance or an HSA/FSA with Bliv?
Bliv documents a self-pay model and says the operator and medical groups do not bill insurance, Medicare, or Medicaid unless expressly stated. Its terms acknowledge that reimbursement or HSA/FSA use may be possible but do not represent that a purchase qualifies. Confirm those questions with the relevant plan or account administrator separately; do not subtract an assumed reimbursement from the amount you expect to pay.
What happens if Bliv's clinician does not offer treatment?
The terms promise a full evaluation-fee refund when a clinician determines you are not a candidate or declines to treat you. Medication is not charged until a prescription is approved. However, the supplied evidence does not state the evaluation fee itself. Once an evaluation is completed and treatment offered, that fee generally becomes nonrefundable unless the purchase terms say otherwise.
Does canceling my Bliv subscription stop a medication order?
No—not by itself. The terms separate subscription cancellation from pending prescription orders, laboratory orders, and appointments. A medication order can be canceled for a full refund before the prescription is transmitted to the pharmacy; afterward, it is nonrefundable. If both a subscription and an order need stopping, explicitly address both rather than relying only on the account's subscription cancellation control.
Does Bliv identify the pharmacy and exact formulation before purchase?
The supplied documents do not identify a particular order's pharmacy or exact formulation. They say the preparing pharmacy's name and contact details appear on the label and in order details. The commercial page describes compounded medicines, while the terms say some medicines may be compounded. Request the specific product and pharmacy information before paying; do not infer an injectable route, ingredient blend, or supply quantity from the drug name.
What does Bliv promise if a delivery is unusable?
Bliv says to report a damaged, incorrect, or unusable shipment within seven days and it will arrange a replacement at no charge. Its terms also offer a medication-charge refund or clinician-approved alternative if the pharmacy cannot fill the prescription. Separately, FDA advises not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or pharmacy to resolve the concern.
Our assessment
Bliv documents more useful payment boundaries than its headline prices alone suggest: conditional medicine-specific minimums, self-pay billing, automatic renewals, evaluation refunds when treatment is declined, and a clear pharmacy-transmission cutoff for medication refunds. Those are meaningful details for comparing financial risk. The unresolved issue is the complete purchase: the supplied evidence does not establish the exact product, supply, first payment, ongoing charge, laboratory inclusions, or financed total. Bliv is therefore best evaluated from a written, individualized quote rather than its $58 or $29 headlines. Before committing, confirm the medication and pharmacy, separate service charges, renewal interval, included follow-up, and the cancellation steps for both subscriptions and orders. The documented process is a useful starting point, but not yet a complete treatment budget.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.